Full-Time

Senior Principal Electrical Engineer

Updated on 8/10/2026

Deadline 8/24/26
Medtronic

Medtronic

10,001+ employees

Medical device maker advancing therapies

Compensation Overview

$164.8k - $247.2k/yr

H1B Sponsorship Available

Mounds View, MN, USA

Hybrid

At least four days on-site per week are required.

Bachelor's, Master's, PhD

Category
Electrical Engineering (1)
Required Skills
Software Testing
Risk Management
SCRUM
FPGA

Get referred to Medtronic

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Electrical Engineering.
  • A minimum of 10 years of electrical systems engineering experience, or an advanced degree with 8 years of electrical systems engineering experience, or a PhD with 6 years of electrical systems engineering experience.
  • For Baccalaureate degrees earned outside the United States, a degree satisfying the requirements of 8 C.F.R. § 214.2(h)(4)(iii)(A) is required.
  • The candidate must possess unrestricted U.S. work authorization at the time of hire and for the duration of employment unless eligible for the stated sponsorship policy.
Responsibilities
  • Represent the electrical engineering team within the RF generator workstream.
  • Lead end-to-end electrical engineering activities across concepts, architecture, circuit card design, fabrication, verification, validation, characterization, integration, and lifecycle support.
  • Own electrical systems development, integration, and electrical characterization for a next-generation RF ablation generator.
  • Ensure rigorous requirements coverage and decomposition from system and product levels to electrical hardware, including test and verification strategies.
  • Partner with systems and functional architects to translate architecture, functionality, and fault-mitigation strategies into executable electrical engineering solutions.
  • Act as the primary technical spokesperson for electrical engineering design decisions, trade studies, and technical reviews within the workstream.
  • Plan and execute design, verification, and design characterization activities.
  • Lead the electrical engineering workstream for major or moderately complex programs, including task planning, delegation, and technical review of work products.
  • Serve as project execution lead and scrum master for electrical engineering activities.
  • Develop and maintain execution plans ensuring all electrical deliverables are appropriately scoped, resourced, and scheduled.
  • Manage schedules and dependencies in collaboration with the research and development lead and Project Management Office partners.
  • Manage day-to-day technical priorities, tradeoffs, and issue resolution within the workstream.
  • Support planning for electrical engineering spend, resourcing, tools, and equipment.
  • Lead and contribute to system and electrical risk management activities, including failure modes and effects analyses, hazard analyses, and risk mitigation strategies.
  • Own identification, assessment, and communication of electrical and system-level risks and emerging issues.
  • Champion consistent application of the quality system, design controls, and best practices across electrical engineering activities.
  • Ensure solutions comply with regulatory, safety, and reliability requirements for medical devices.
  • Ensure cross-functional alignment across systems, software, manufacturing, quality, and program teams.
  • Translate electrical design intent and requirements to manufacturing partners to ensure producibility and design-transfer readiness.
  • Provide regular and ad hoc technical and program updates to functional and program leadership.
  • Communicate emerging issues, escalations, and risk status to CTM and other stakeholders.
  • Provide technical guidance, coaching, and mentorship to engineers across the organization.
  • Influence engineering standards, best practices, and continuous-improvement initiatives to mature electrical engineering capability.
Desired Qualifications
  • Experience with electromechanical systems or capital equipment, including hardware and software integration.
  • Technical leadership experience.
  • Experience with IEC 60601-1 or another highly regulated industry.
  • Experience with RF energy delivery, SOMs, and field-programmable gate arrays.
  • Experience with ISO 14971.
  • Experience with product concept development, customer interaction, systems engineering, verification of engineering requirements, and validation of customer needs or design requirements.

Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Fridley, Minnesota

Founded

1949

Get referred to Medtronic

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 3, 2026, Medtronic posted its highest annual revenue growth in ten years.
  • December 2025 Hugo clearance and June 2026 510(k) filings expand U.S. robotic surgery reach.
  • July 2026 SPR acquisition and ViaVerte launch strengthen non-opioid pain therapy growth.

What critics are saying

  • August 4, 2026, a jury ordered $88 million over Covidien hernia-mesh injuries.
  • February 5, 2026, Medtronic lost a $382 million antitrust verdict to Applied Medical.
  • MiniMed separation and $300–$500 million restructuring through 2029 distract management and compress margins.

What makes Medtronic unique

  • Medtronic spans 70 conditions, from cardiac devices to robotic surgery, globally.
  • Hugo, Touch Surgery Aide, and NVIDIA integration create a connected surgery stack.
  • Pulse Field Ablation and Affera give Medtronic durable electrophysiology differentiation in 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Employee Assistance Program

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

1%
Yahoo Finance
Aug 8th, 2026
Medtronic and Intuitive Surgical lag market amid sector weakness

Medtronic and Intuitive Surgical, two medical device leaders, have underperformed this year due to sector weakness and company-specific challenges. However, both show potential for recovery. Medtronic's fourth-quarter revenue rose 9.9% to $9.8 billion, though adjusted earnings per share fell 4.3% to $1.55 due to higher costs, including tariffs. The company posted its highest annual revenue growth in a decade, driven partly by its Pulse Field Ablation franchise. Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, positioning it to compete in the underpenetrated robotic surgery market. The company plans to spin off its lower-margin diabetes care division, which should improve margins. With a 3.4% forward dividend yield and 49 consecutive years of payout increases, Medtronic appeals to income-focused investors.

PR Newswire
Aug 6th, 2026
Medtronic's Sphere-9 catheter receives expanded CE Mark for ventricular arrhythmia treatment

Medtronic has received expanded CE Mark approval for its Affera Mapping and Ablation System with Sphere-9 Catheter to treat ventricular arrhythmias, including ventricular tachycardia and premature ventricular complexes. The Sphere-9 catheter is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter CE marked for ventricular ablation. The US Food and Drug Administration granted Breakthrough Device Designation for the Sphere-9 catheter, providing an expedited regulatory pathway. The Sphere VT pivotal trial is now enrolling patients to support future US approval. The system combines pulsed field and radiofrequency ablation with high-definition mapping in a single catheter. Medtronic says the technology addresses an unmet need in treating ventricular arrhythmias, where outcomes have remained suboptimal with limited recent innovation in ablation tools.

MMail
Jul 31st, 2026
Medtronic invests in CoreMap's oversubscribed $37m Series C round.

Medtronic invests in CoreMap's oversubscribed $37m Series C round. July 31, 2026 The funds raised will enable CoreMap to develop more precise data-driven tools to address atrial fibrillation ablation. Read more: Medtronic invests in CoreMap's oversubscribed $37m Series C round.

EIN Presswire
Jul 29th, 2026
CoreMap raises $37M Series C led by Medtronic for next-generation AF mapping platform

CoreMap, a medical technology company developing tools for atrial fibrillation (AF) treatment, has closed an oversubscribed $37 million Series C financing round. Medtronic led the investment, with participation from existing and new investors. The Burlington, Massachusetts-based company will use the funding to accelerate development of its next-generation AF mapping platform. CoreMap's technology uses high-density mapping and advanced data analytics to provide physicians with more precise guidance for AF ablation procedures. Chief executive officer Sarah Kalil said the investment enables CoreMap to pursue its vision of providing electrophysiologists with clearer understanding of AF for more targeted, personalised treatment. Chris Eso, global head of corporate and business development at Medtronic, noted that CoreMap is addressing critical unmet needs in AF treatment with differentiated technology and strong clinical support. Founded in 2016, CoreMap develops electrophysiology mapping systems based on large datasets of electrical activation data.

Medical Device Network
Jul 27th, 2026
Medtronic continues assembly of industry's "broadest" pain therapy portfolio.

Medtronic continues assembly of industry's "broadest" pain therapy portfolio. Medtronic formally launched ViaVerte at ASPN 2026, with its $650m acquisition of SPR Therapeutics completing at the meeting's outset on 16 July. Bolstered by a recent $650m deal and a new device launch, Medtronic's pain therapy product lineup is going from strength to strength. Medtronic's completed acquisition of SPR Therapeutics this July, along with its recent formal rollout of the ViaVerte basal nerve ablation system, avails the medtech giant of the "broadest pain therapy portfolio in the industry", a Medtronic executive has asserted. ViaVerte is a basivertebral nerve ablation (BVNA) system that delivers radiofrequency (RF) ablation to destroy the small nerve within the vertebral body that is responsible for transmitting pain signals associated with chronic lower-back pain. Originally developed by Merit Medical, Medtronic signed a distribution deal for the system in March 2026. Following the agreement, Medtronic formally launched ViaVerte, which secured US Food and Drug Administration (FDA) clearance in March 2026, at the 2026 American Society of Pain and Neuroscience (ASPN) meeting, which took place 16-19 July in Miami. Meanwhile, Medtronic completed its $650m acquisition of SPR Therapeutics on 16 July. The Ohio-based company's lead product is SPRINT, a peripheral nerve stimulation (PNS) system for addressing chronic pain and expands Medtronic's existing chronic pain lineup. According to GlobalData analysis, the global neuromodulation device market is projected to reach a valuation of over $13bn in 2035, up from around $6.8bn in 2025. Ashwini Sharan, CMO at Medtronic Neuromodulation, tells Medical Device Network the addition of SPR's core product and ViaVerte strengthens what the company believes is the "broadest pain therapy portfolio in the industry" while also reinforcing Medtronic's ability to serve patients of pain care "with evidence-based, non-opioid treatment options". Sharan continues: "The launch of ViaVerte, together with its acquisition of SPR Therapeutics, reflects its commitment to expanding patient access to innovative, minimally invasive pain therapies. "ViaVerte complements our existing pain interventions portfolio by giving physicians an additional option for appropriately selected patients with vertebrogenic chronic low back pain, while SPRINT expands our ability to address both chronic and acute pain through short-term peripheral nerve stimulation." Regarding ViaVerte's rollout in the US, Sharan says the company is taking a "thoughtful, phased approach to commercialisation" in order to satisfy dictates around the BVNA system, including clinical support and patient access. "Our focus is on ensuring clinicians have the training and resources needed to successfully integrate the therapy into practice while expanding access responsibly. As adoption continues to grow, we'll build on our commercial infrastructure and physician-support network to broaden availability," Sharan explains. "Whether it's for ViaVerte for vertebrogenic pain or SPRINT for chronic and acute pain, we're focused on expanding access to innovative, non-opioid therapies that support individualised treatment decisions and meaningful improvements in patients' quality of life," he concludes. Give your business an edge with its leading industry insights.